Johnson & Johnson (JNJ) Stock Rating Reaffirmed by UBS AG
Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reaffirmed by investment analysts at UBS AG in a report issued on Saturday. They presently have a $148.00 price target on the stock. UBS AG’s price objective points to a potential upside of 13.84% from the company’s previous close.
Other equities analysts have also recently issued research reports about the company. Morgan Stanley lifted their target price on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 5th. Cowen and Company set a $147.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, August 24th. BidaskClub lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. Finally, Jefferies Group LLC restated a “hold” rating and set a $140.00 price target on shares of Johnson & Johnson in a report on Friday, June 16th. Six analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $135.52.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 130.01 on Friday. The company has a market cap of $348.95 billion, a price-to-earnings ratio of 22.00 and a beta of 0.79. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The stock has a 50 day moving average price of $132.79 and a 200-day moving average price of $129.43.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the previous year, the firm posted $1.74 earnings per share. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Stock Rating Reaffirmed by UBS AG” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-stock-rating-reaffirmed-by-ubs-ag/1601952.html.
In related news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
A number of institutional investors have recently modified their holdings of JNJ. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.7% during the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after purchasing an additional 6 shares in the last quarter. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares in the last quarter. Institutional investors own 65.90% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.